🔗 Share this article

Given that America continues making sweeping adjustments to its vaccination guidelines, an unexpected name appears somewhat surprisingly: Høeg, a Danish American sports physician and epidemiologist who initially gained attention by casting doubt on coronavirus vaccines in the global health crisis and has concentrated on alleged deaths after Covid vaccination in her short position at the FDA.

Scheduled Changes to Childhood Vaccine Schedule

Agency leaders were set to announce sweeping changes to the childhood vaccination calendar recently, aligning the US with Denmark’s vaccine program, it is understood – a substantial departure that would place the US out of step with a large portion of the world with insufficient data for improved outcomes. The planned update has been delayed until the new year.

Instead of the top vaccines chief, Tracy Beth Høeg is scheduled to address the audience at the gathering. She was recently named temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to head the center this year.

A New Direction at the FDA

The acting appointment could signify a tighter collaboration between the pharmaceutical and biologics branches as Dr. Høeg and Prasad solidify control at the FDA – and it points to a greater focus upon dismantling long-standing immunizations at the FDA.

Dr. Høeg has repeatedly called for halting specific pediatric immunization guidelines in the US so as to align more in line with Denmark's approach, a society with nationalized medicine and a population roughly the population of the state of Wisconsin.

In her initial comments, she has persisted in emphasizing on immunizations – traditionally the responsibility of Prasad, chief of the FDA’s CBER – instead of drug regulation.

Questions Over Expertise

The appointee has little discernible experience in drug development, approval processes or leadership, which has been standard for past heads of the biologics center. She has worked at the FDA as a senior adviser to the commissioner and the vaccine center since earlier this year.

“She appears not to have any of the qualifications” for leading the drug-regulation department, stated Dr. Jonathan Howard. “She’s never run a clinical trial. She lacks experience in managing a sizeable institution. She is not an expert in drug approvals.”

Past heads of the center would “understand laws and regulations and the science of medication creation”, noted a former acting FDA commissioner. “Objectively, she doesn’t have the type of experience that previous people who headed CBER have had.”

CDER has an vast range of responsibilities at the agency, Woodcock emphasized.

“Everybody just zeroes in on the novel medication approvals, but the off-patent medication office authorizes numerous generic medications. There is also a biosimilars program, OTC medication office and other areas, and every single one have to be supervised,” Dr. Woodcock said. “The thing you neglect, that is precisely what that I always told people is going to come back to haunt you.”

Additionally, a substantial leadership component to the position, which manages more than 5,000 employees. “It’s a massive leadership role, if you do it right,” she added.

Response and Contentious Programs

In response to questions about Høeg’s credentials and whether this assignment indicates greater collaboration among FDA leaders on vaccines, a press secretary responded that the “concerns stem from flawed presumptions”.

“Her resume matches the duties of her job,” the official said, pointing to the time Dr. Høeg spent guiding the FDA commissioner on “medication safety and approval science, including computational safety modeling and vaccine surveillance”.

As acting director, Dr. Høeg assumes responsibility for the agency head's recently launched priority voucher program, a disputed rapid drug-approval program that reportedly concerned her preceding directors. “By what process are these medications being chosen for this fast-track system? Who makes the decisions?” Howard said. “There is a lot of confidentiality occurring at the FDA right now.”

In general, he said, “the FDA appears to be shifting towards more relaxed oversight of all drugs, except for shots.”

Documented Track Record on Vaccines

Regarding immunizations, Høeg has a clearer, if troubling, history, Howard said. She released a research paper using non-validated public submissions to assess the incidence of heart inflammation after COVID-19 immunization. She advised the state of Florida top health official Joseph Ladapo, who reportedly have changed statistics to imply Covid vaccinations are pose a greater threat than they are.

Included in her “policy goals” for the current administration featured changing regulations for novel immunizations and halting “unnecessary” immunizations, she stated after the election on a podcast. At the agency, Høeg has allegedly floated the idea of barring teenage boys from obtaining COVID-19 vaccinations.

“She’s an thorough ideologue who begins with her conclusions and works backwards to accommodate the evidence in a very deceptive, untruthful way,” Howard stated.

Taking Control and a “Push for Payback”

Høeg aligned with fellow dissenters, {like|